Hematologic Malignancies Demystified - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Hematologic Malignancies Demystified

A Critical Appraisal of Data From 2019

Not a member of My prIME? Join now for instant access.

Explore the options in benign hematology and hematologic malignancies with these downloadable slides. Expert faculty examine updates from recent congresses and present the latest clinically relevant data.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Feb 11, 2020

Expiration Date

Feb 11, 2021

Author(s) Byline

  • Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
  • Jonathan Kaufman, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Featured Topic

Frontline multiple myeloma

Author(s) Byline

  • Kenneth Anderson, MD, Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts, United States
  • Keith Stewart, MB, ChB, Mayo Clinic, Scottsdale, Arizona, United States

Featured Topic

Relapsed/refractory multiple myeloma

Author(s) Byline

  • Ayalew Tefferi, MD, Mayo Clinic College of Medicine, Rochester, Minnesota, United States

Featured Topic

Myeloproliferative neoplasms

Author(s) Byline

  • Elias Jabbour, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Acute lymphoblastic leukemia

Author(s) Byline

  • Jorge Cortes, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Chronic myeloid leukemia

Author(s) Byline

  • Guillermo Garcia-Manero, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Myelodysplastic syndromes

Author(s) Byline

  • Courtney DiNardo, MD, The University of Texas , MD Anderson Cancer Center, Houston, Texas, United States
  • Alexander E. Perl, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Richard M. Stone, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Acute myeloid leukemia

Author(s) Byline

  • Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Susan O'Brien, MD, UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange, California, United States

Featured Topic

Chronic lymphocytic leukemia

Author(s) Byline

  • Parameswaran Venugopal, MD, Rush University, Chicago, Illinois, United States
  • Anas Younes, MD, Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Featured Topic

Hodgkin lymphoma and indolent non-Hodgkin lymphoma

Author(s) Byline

  • Christopher Flowers, MD, The University of Texas , MD Anderson Cancer Center , Houston, Texas, United States
  • Julie Vose, MD, MBA, University of Nebraska Medical Center, Omaha, Nebraska, United States

Featured Topic

Aggressive non-Hodgkin lymphoma

Author(s) Byline

  • Stephan Moll, MD, University of North Carolina, School of Medicine, Chapel Hill, North Carolina, United States

Featured Topic

Benign hematology

This educational activity is specifically designed for hematologists/oncologists, nurses, nurse practitioners, and other healthcare professionals who are involved or interested in the management of patients with hematologic malignancies and disorders.

Upon completion of this activity, physicians will demonstrate:

  • Increased knowledge regarding the
    • Emerging clinical trial data investigating established and novel treatments for hematologic malignancies and disorders
    • Methods to assess and monitor treatment response in patients with hematologic malignancies or disorders
    • Treatment-related side effects in patients with hematologic malignancies or disorders
  • Greater competence related to
    • Individualizing treatment in patients with hematologic malignancies or disorders

Upon completion of this activity, nurses will demonstrate:

  • Increased knowledge regarding the
    • Emerging clinical trial data investigating established and novel treatments for hematologic malignancies and disorders
    • Treatment-related side effects in patients with hematologic malignancies or disorders

This activity is supported by AstraZeneca Pharmaceuticals LP, Celgene Corporation, Jazz Pharmaceuticals, and Seattle Genetics, Inc.

Slides From a Certified Activity

These slides, derived from a certified live event, contain content that is evidence-based, balanced, and free of commercial bias. While the content of the certified live activity was planned and implemented by Medscape, LLC and prIME Oncology, these slides do not offer continuing education credit.

Provider

This activity is jointly provided by Medscape, LLC and prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Kenneth C. Anderson, MD
Disclosure: Kenneth C. Anderson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Celgene Corporation; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Millennium Pharmaceuticals, Inc.; Precision BioSciences; Sanofi
Receipt of Intellectual Property Rights/patent holder: C4 Therapeutics; Oncopeptides

Martha L. Arellano, MD
Disclosure: Martha L. Arellano, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.

Jorge Cortes, MD
Disclosure: Jorge Cortes, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda Pharmaceuticals North America, Inc.

Courtney D. DiNardo, MD, MSCE
Disclosure: Courtney D. DiNardo, MD, MSCE, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Agios Pharmaceuticals; Celgene Corporation; Daiichi Sankyo, Inc.; Jazz Pharmaceuticals, Inc.; Notable Labs
Received grants for clinical research from: AbbVie Inc.; Agios Pharmaceuticals; Celgene Corporation; Daiichi Sankyo, Inc.
Owns less than 5% stock, stock options, or bonds from: Notable Labs

Christopher Flowers, MD
Disclosure: Christopher Flowers, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bayer AG; Celgene Corporation; Denovo Biopharma; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Karyopharm Therapeutics; MEI Pharma; Pharmacyclics, Inc.; Roche; Spectrum Pharmaceuticals, Inc.
Received grants for clinical research from: AbbVie Inc.; Acerta Pharma, LLC; Burroughs Wellcome Fund; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Millennium Pharmaceuticals, Inc.; Pharmacyclics, Inc.; Roche; Takeda Pharmaceuticals North America, Inc.; TG Therapeutics, Inc.

Guillermo Garcia-Manero, MD
Disclosure: Guillermo Garcia-Manero, MD, has disclosed no relevant financial relationships.

Elias Jabbour, MD
Disclosure: Elias Jabbour, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AbbVie Inc.; Adaptive Biotechnologies; Amgen Inc.; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Spectrum Dynamics Ltd; Takeda Pharmaceuticals North America, Inc.

Hagop M. Kantarjian, MD
Disclosure: Hagop M. Kantarjian, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: AbbVie Inc.; Agios Pharmaceuticals; Amgen Inc.; ARIAD Pharmaceuticals, Inc.; Astex Pharmaceuticals; Bristol-Myers Squibb Company; Cyclacel Limited; Daiichi Sankyo, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Received honoraria from: AbbVie Inc.; Actinium Pharmaceuticals; Agios Pharmaceuticals; Amgen Inc.; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.

Jonathan Kaufman, MD
Disclosure: Jonathan Kaufman, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Karyopharm Therapeutics; Sanofi; Takeda Pharmaceuticals North America, Inc.; Tecnofarma; TG Therapeutics, Inc.
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Fortis Therapeutics, Inc.; Genentech, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Sutro Biopharma
Received honoraria from: Tecnofarma
Received travel support from: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Sanofi; Takeda Pharmaceuticals North America, Inc.

Sagar Lonial, MD
Disclosure: Sagar Lonial, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Karyopharm Therapeutics; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.

Anthony Mato, MD
Disclosure: Anthony Mato, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pharmacyclics, Inc.; Regeneron Pharmaceuticals, Inc.; TG Therapeutics, Inc.
Received grants for clinical research from: AbbVie Inc.; TG Therapeutics, Inc.

Stephan Moll, MD
Disclosure: Stephan Moll, MD, has disclosed no relevant financial relationships.

Susan O’Brien, MD
Disclosure: Susan O’Brien, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Alexion Pharmaceuticals, Inc.; Amgen Inc.; Aptose Biosciences; Astellas Pharma, Inc.; Celgene Corporation; Eisai Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Pfizer Inc.; Pharmacyclics, Inc.; Sunesis Pharmaceuticals, Inc.; TG Therapeutics, Inc.; Vaniam Group LLC; Verastem
Received grants for clinical research from: Acerta Pharma, LLC; Gilead Sciences, Inc.; Kite Pharma Inc.; Pfizer Inc.; Pharmacyclics, Inc.; Regeneron; Sunesis Pharmaceuticals, Inc.; TG Therapeutics, Inc.

Alexander E. Perl, MD
Disclosure: Alexander E. Perl, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Actinium Pharmaceuticals; Agios Pharmaceuticals; Arog Pharamaceuticals, Inc; Astellas Pharma, Inc.; Daiichi Sankyo, Inc.; Forma Therapeutics; Loxo; NewLink Genetics Corporation; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: AbbVie Inc.; Astellas Pharma, Inc.; Bayer AG; Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation

Keith Stewart, MB, ChB
Disclosure: Keith Stewart, MB, ChB, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Ionis Pharmaceuticals; Janssen Pharmaceuticals; Oncopeptides; Ono Pharmaceutical Co., Ltd.; Roche; Seattle Genetics, Inc.; Takeda Pharmaceuticals North America, Inc.; Veritas Genetics
Received grants for clinical research from: Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals

Richard M. Stone, MD
Disclosure: Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Actinium Pharmaceuticals; Agios Pharmaceuticals; Amgen Inc.; Astellas Pharma, Inc.; BioLineRx; Celgene Corporation; Daiichi Sankyo, Inc.; GEMoaB Monoclonals GmbH; Janssen Pharmaceuticals; MacroGenics; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.; TrovaGene
Served as a speaker or a member of a speakers bureau for: Daiichi Sankyo, Inc.
Received grants for clinical research from: Arog Pharmaceuticals, Inc; Novartis Pharmaceuticals Corporation

Ayalew Tefferi, MD
Disclosure: Ayalew Tefferi, MD, has disclosed no relevant financial relationships.

Parameswaran Venugopal, MD
Disclosure: Parameswaran Venugopal, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bayer AG

Julie Vose, MD, MBA
Disclosure: Julie Vose, MD, MBA, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Epizyme, Inc.; Janssen Pharmaceuticals; Karyopharm Therapeutics; Kite Pharma Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; Pharmacyclics, Inc.; Vaniam Group; Verastem Oncology
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Celgene Corporation; Incyte Corporation; Kite Pharma Inc.; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.

Anas Younes, MD
Disclosure: Anas Younes, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BioPath; Celgene Corporation; Epizyme, Inc.; Hutchison MediPharma; Roche; Xynomic Pharma
Received grants for clinical research from: Bristol-Myers Squibb Company; Curis, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Roche; Syndax Pharmaceuticals, Inc.

  • Jamieson Bretz, PhD, has disclosed no relevant financial relationships.
  • Melinda Tanzola, PhD, has disclosed no relevant financial relationships.
  • Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC and prIME Oncology staff have disclosed that they have no relevant financial relationships.

Content Reviewer

  • Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.